Literature DB >> 17943915

Psychotherapies for hypochondriasis.

A B Thomson1, L A Page.   

Abstract

BACKGROUND: Hypochondriasis is associated with significant medical morbidity and high health resource use. Recent studies have examined the treatment of hypochondriasis using various forms of psychotherapy.
OBJECTIVES: To examine the effectiveness and comparative effectiveness of any form of psychotherapy for the treatment of hypochondriasis. SEARCH STRATEGY: 1. CCDANCTR-Studies and CCDANCTR-References were searched on 7/8/2007, CENTRAL, Medline, PsycINFO, EMBASE, Cinahl, ISI Web of Knowledge, AMED and WorldCat Dissertations; Current Controlled Trials meta-register (mRCT), CenterWatch, NHS National Research Register and clinicaltrials.gov; 2. Communication with authors of relevant studies and other clinicians in the field; 3. Handsearching reference lists of included studies and relevant review articles, and electronic citation search in ISI Web of Knowledge for all included studies. SELECTION CRITERIA: All randomised controlled studies, both published and unpublished, in any language, in which adults with hypochondriasis were treated with a psychological intervention. DATA COLLECTION AND ANALYSIS: Data were extracted independently by two authors using a standardised extraction sheet. Study quality was assessed independently by the two authors qualitatively and using a standardised scale. Meta-analyses were performed using RevMan software. Standardised or weighted mean differences were used to pool data for continuous outcomes and odds ratios were used to pool data for dichotomous outcomes, together with 95% confidence intervals. MAIN
RESULTS: Six studies were included, with a total of 440 participants. The interventions examined were cognitive therapy (CT), behavioural therapy (BT), cognitive behavioural therapy (CBT), behavioural stress management (BSM) and psychoeducation. All forms of psychotherapy except psychoeducation showed a significant improvement in hypochondriacal symptoms compared to waiting list control (SMD (random) [95% CI] = -0.86 [-1.25 to -0.46]). For some therapies, significant improvements were found in the secondary outcomes of general functioning (CBT), resource use (psychoeducation), anxiety (CT, BSM), depression (CT, BSM) and physical symptoms (CBT). These secondary outcome findings were based on smaller numbers of participants and there was significant heterogeneity between studies. AUTHORS'
CONCLUSIONS: Cognitive therapy, behavioural therapy, cognitive behavioural therapy and behavioural stress management are effective in reducing symptoms of hypochondriasis. However, studies included in the review used small numbers of participants and do not allow estimation of effect size, comparison between different types of psychotherapy or whether people are "cured". Most long-term outcome data were uncontrolled. Further studies should make use of validated rating scales, assess treatment acceptability and effect on resource use, and determine the active ingredients and nonspecific factors that are important in psychotherapy for hypochondriasis.

Entities:  

Mesh:

Year:  2007        PMID: 17943915     DOI: 10.1002/14651858.CD006520.pub2

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  27 in total

Review 1.  Should an obsessive-compulsive spectrum grouping of disorders be included in DSM-V?

Authors:  Katharine A Phillips; Dan J Stein; Scott L Rauch; Eric Hollander; Brian A Fallon; Arthur Barsky; Naomi Fineberg; David Mataix-Cols; Ygor Arzeno Ferrão; Sanjaya Saxena; Sabine Wilhelm; Megan M Kelly; Lee Anna Clark; Anthony Pinto; O Joseph Bienvenu; Joanne Farrow; James Leckman
Journal:  Depress Anxiety       Date:  2010-06       Impact factor: 6.505

Review 2.  Cognitive-behavioral and pharmacological interventions for premenstrual syndrome or premenstrual dysphoric disorder: a meta-analysis.

Authors:  Maria Kleinstäuber; Michael Witthöft; Wolfgang Hiller
Journal:  J Clin Psychol Med Settings       Date:  2012-09

Review 3.  Validity of Current Treatment Protocols to Overcome Hypochondriasis.

Authors:  Shrayash Khare; Meher Narain Srivastava
Journal:  J Clin Diagn Res       Date:  2017-01-01

4.  Guided Internet-based vs. face-to-face cognitive behavior therapy for psychiatric and somatic disorders: a systematic review and meta-analysis.

Authors:  Gerhard Andersson; Pim Cuijpers; Per Carlbring; Heleen Riper; Erik Hedman
Journal:  World Psychiatry       Date:  2014-10       Impact factor: 49.548

5.  A clinician-administered severity rating scale for illness anxiety: development, reliability, and validity of the H-YBOCS-M.

Authors:  Natalia A Skritskaya; Amanda R Carson-Wong; James R Moeller; Sa Shen; Arthur J Barsky; Brian A Fallon
Journal:  Depress Anxiety       Date:  2012-04-13       Impact factor: 6.505

6.  A Randomized Controlled Trial of Medication and Cognitive-Behavioral Therapy for Hypochondriasis.

Authors:  Brian A Fallon; David K Ahern; Martina Pavlicova; Iordan Slavov; Natalia Skritskya; Arthur J Barsky
Journal:  Am J Psychiatry       Date:  2017-06-29       Impact factor: 18.112

7.  The Efficacy of Cognitive Behavioral Therapy: A Review of Meta-analyses.

Authors:  Stefan G Hofmann; Anu Asnaani; Imke J J Vonk; Alice T Sawyer; Angela Fang
Journal:  Cognit Ther Res       Date:  2012-07-31

Review 8.  Advances in understanding illness anxiety.

Authors:  Kelli J Harding; Natalia Skritskaya; Emily Doherty; Brian A Fallon
Journal:  Curr Psychiatry Rep       Date:  2008-08       Impact factor: 5.285

9.  Do psychiatric comorbidities influence inpatient death, adverse events, and discharge after lower extremity fractures?

Authors:  Mariano E Menendez; Valentin Neuhaus; Arjan G J Bot; Mark S Vrahas; David Ring
Journal:  Clin Orthop Relat Res       Date:  2013-06-30       Impact factor: 4.176

10.  Severe MUPS in a sick-listed population: a cross-sectional study on prevalence, recognition, psychiatric co-morbidity and impairment.

Authors:  Rob Hoedeman; Boudien Krol; Nettie Blankenstein; Petra C Koopmans; Johan W Groothoff
Journal:  BMC Public Health       Date:  2009-12-01       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.